Mednax, Inc (MD) Hits New 12-Month Low at $41.48
Mednax, Inc (NYSE:MD)’s share price hit a new 52-week low on Thursday . The company traded as low as $41.48 and last traded at $41.53, with a volume of 564,839 shares traded. The stock had previously closed at $42.55.
A number of equities research analysts have issued reports on the company. Stephens upgraded Mednax from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $55.00 to $68.00 in a research note on Thursday, June 22nd. Stifel Nicolaus cut their price target on Mednax from $65.00 to $58.00 and set a “hold” rating for the company in a research note on Thursday, May 25th. Mizuho cut their price target on Mednax from $64.00 to $58.00 and set a “neutral” rating for the company in a research note on Tuesday, May 30th. BidaskClub upgraded Mednax from a “strong sell” rating to a “sell” rating in a research note on Tuesday, June 13th. Finally, Jefferies Group LLC set a $46.00 price target on Mednax and gave the company a “hold” rating in a research note on Sunday, July 30th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and one has issued a buy rating to the stock. Mednax currently has an average rating of “Hold” and an average target price of $59.88.
The stock’s 50-day moving average price is $45.56 and its 200 day moving average price is $58.00. The company has a market capitalization of $3.87 billion, a P/E ratio of 13.37 and a beta of 0.40.
Mednax (NYSE:MD) last announced its quarterly earnings results on Friday, July 28th. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.04. The company had revenue of $843 million during the quarter, compared to analysts’ expectations of $849.49 million. Mednax had a return on equity of 11.89% and a net margin of 8.78%. Mednax’s quarterly revenue was up 9.2% on a year-over-year basis. During the same period last year, the business earned $1.03 earnings per share. Analysts predict that Mednax, Inc will post $3.31 earnings per share for the current year.
In related news, Director Md Pascal J. Goldschmidt sold 1,969 shares of Mednax stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total transaction of $113,355.33. Following the completion of the transaction, the director now directly owns 18,072 shares in the company, valued at $1,040,405.04. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.40% of the stock is currently owned by company insiders.
Hedge funds have recently made changes to their positions in the stock. Eagle Boston Investment Management Inc. raised its position in Mednax by 12.9% during the second quarter. Eagle Boston Investment Management Inc. now owns 191,636 shares of the company’s stock valued at $11,569,000 after acquiring an additional 21,895 shares in the last quarter. JPMorgan Chase & Co. raised its position in Mednax by 55.2% during the first quarter. JPMorgan Chase & Co. now owns 79,610 shares of the company’s stock valued at $5,524,000 after acquiring an additional 28,301 shares in the last quarter. Mn Services Vermogensbeheer B.V. raised its position in Mednax by 527.2% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 15,228 shares of the company’s stock valued at $919,000 after acquiring an additional 12,800 shares in the last quarter. Prudential Financial Inc. raised its position in Mednax by 7.9% during the first quarter. Prudential Financial Inc. now owns 58,520 shares of the company’s stock valued at $4,060,000 after acquiring an additional 4,270 shares in the last quarter. Finally, Achmea Investment Management B.V. purchased a new position in Mednax during the first quarter valued at approximately $966,000.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.